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memorablefaculty
Penn Vet Faculty for the Future
BY SUSAN I. FINKELSTEIN
t’s all about heart—at least, that is, for Dr. Mark Oyama,
associate professor of cardiology, and Dr. Meg Sleeper,
chief of the Cardiology Section of the Matthew J. Ryan
Veterinary Hospital.Their research into diagnosing and curing
heart disease can benefit not only the dogs that are the focus
of their work, but also people—whose hearts, literally and
figuratively, already benefit so much from their connections
with these quintessential companion animals.
Like people, dogs can suffer from both congenital and
“acquired” heart disease—and even with the development of
new technology and medications, even with an ever-broadening knowledge base about the causes and courses of heart
disease, illness and death in dogs with heart problems
remains high. According to the American Veterinary Medical
Association, approximately 3.2 million dogs in the United
States that have annual veterinary examinations suffer from
some form of acquired heart disease and may be in heart
failure. And because of the genetic similarities between dogs
and people, the study of many congenital defects that affect
one species can lead to breakthroughs with both.
Dr. Oyama has studied how stem cell research might be
used to treat dogs with heart disease. Before he came to Penn
from the University of Illinois College of Veterinary
Medicine in 2005, he investigated how damaged heart cells
in dogs could be repaired by transplanting the animals’ own
stem cells into their hearts—a process known as cardiac cellular transplantation. But the fundamental biological processes
that govern the behavior of these cells remains a mystery, as
does the long-term efficacy of the procedure.
“I think people get excited about it because of the huge
potential that it has,” Dr. Oyama says.“Even in people, it’s an
area about which very little is known.When they’re doing stem
cell transplants in people, yes, it appears to improve the heart
function, but when you ask the scientists ‘How is it doing that?’
nobody knows.They don’t have any idea. Cells go in there, and
somehow they’re making the heart function better.”
Cardiac cellular transplantation could have a marked effect
in treating dilated cardiomyopathy, or DCM, the second-mostcommon acquired heart disease in dogs. Some large breeds,
such as Dobermans, great Danes and boxers, are particularly
prone to it. DCM causes the heart muscle to lose strength and
fail to pump blood properly, and can eventually lead to heart
failure.To identify genes that may play a role in the process of
the disease, Dr. Oyama and his colleagues used a commercially
available gene chip, or microarray, designed for dogs—a 1.5inch square that contains more than 23,000 genes.When
exposed to the genetic material from Doberman dogs that had
died from heart disease, genes on the chip lit up if they were
active in the sample.The researchers knew the nature and
location of the genes on the chip, so they could identify the
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active genes in the
samples and determine
their level of activity
by the brightness of
the fluorescence.
Essentially all 23,000
genes, tested at once,
were narrowed down
to 167 genes that
Drs. Mark Oyama and Meg Sleeper examine
could play a role in the
a patient. Photo by John Donges.
development of DCM.
Dr. Sleeper, too, has focused on DCM in dogs—but her
work primarily has been on treatment. “My primary
research interest is therapeutic gene transfer,” says Dr.
Sleeper. “Basically, with the procedure in which I am interested, we inject genetic material into the patient’s myocardial cells using a catheter-based approach and a virus, which
is not capable of replicating (infection).These cells then produce the gene product: one of several proteins that improve
myocardial function.We currently are in the process of proving safety, and once that is complete, my goal is to offer this
technique as a therapeutic option for dogs with DCM.”The
procedure also offers great potential for humans—and in late
2008 Dr. Sleeper spent time in China treating monkeys to
evaluate its feasibility in non-human primates.
A paper published recently in the Journal of the American
Veterinary Medical Association (Vol. 233, No. 1, July 2008) and
co-authored by Drs. Oyama and Sleeper, as well as Dr. Dottie
Brown, associate professor of surgery and associate director
of the Veterinary Clinical Investigations Center at Ryan
Veterinary Hospital, and other colleagues, attempts to better
define the importance of quality versus quantity of life in dogs
and cats with heart disease. Probably the first investigation of
these issues, the report reveals that successful treatment of heart
disease in dogs must acknowledge owner’s perceptions and priorities with regard to their dogs’ quality of life.
“What is more important to owners?” asks Dr. Oyama.
“Do they value long life or high quality when forced to
reach a balance between the two?”The paper finds that
owners of dogs with cardiac disease highly value their pets’
quality of life—and that veterinarians need to address these
issues to ensure that the care provided is directed toward the
desired goals. Furthermore, veterinarians should continue to
help owners reassess their priorities as their pets’ clinical circumstances change. Clinical trials similar to those carried
out by the Veterinary Clinical Investigations Center in
which therapies for heart disease in dogs are tested should
include quality-of-life concerns as endpoints, and future
studies also should seek ways to better measure these goals.
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